The focus of the present application is to better define some of the molecular events which underlie the initiation and progression of thyroid malignancies. The investigator postulates that the potential for thyroid cell transformation is determined in part by the nature of the genetic events responsible for the initiation of the tumor clone, and specifically is dependent on whether these events promote genetic instability. In this proposal, they will examine the role of individual thyroid tumor initiating events on indicators of chromosomal stability in vitro. The major emphasis will be to determine the effect of inducible expression of several oncogene products on the generation of anomalous chromosome structures and mitosis, on the rate of gene amplification, and on generation of DNA strand breaks. In addition, the investigators will examine the phenotypic impact of inducing thyroid-specific expression of wild-type and mutant PKC alpha isoforms in transgenic mice. Finally, the role of mutations of PKC alpha in the control of thyroid-differentiated gene expression will be studied.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072597-04
Application #
6124529
Study Section
Endocrinology Study Section (END)
Program Officer
Freeman, Colette S
Project Start
1996-12-21
Project End
2001-11-30
Budget Start
1999-12-08
Budget End
2000-11-30
Support Year
4
Fiscal Year
2000
Total Cost
$283,748
Indirect Cost
Name
University of Cincinnati
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D et al. (2018) EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discov :
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Knauf, Jeffrey A; Luckett, Kathleen A; Chen, Kuen-Yuan et al. (2018) Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. J Clin Invest 128:4086-4097
Ibrahimpasic, Tihana; Xu, Bin; Landa, Iñigo et al. (2017) Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clin Cancer Res 23:5970-5980
Montero-Conde, Cristina; Leandro-Garcia, Luis J; Chen, Xu et al. (2017) Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proc Natl Acad Sci U S A 114:E4951-E4960
Fagin, James A; Wells Jr, Samuel A (2016) Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 375:1054-67
Landa, Iñigo; Ibrahimpasic, Tihana; Boucai, Laura et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-66
Nagarajah, James; Le, Mina; Knauf, Jeffrey A et al. (2016) Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 126:4119-4124
Garcia-Rendueles, Maria E R; Ricarte-Filho, Julio C; Untch, Brian R et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov 5:1178-93
Dunn, Lara; Fagin, James A (2015) Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. Nat Rev Endocrinol 11:325-7

Showing the most recent 10 out of 57 publications